The New England journal of medicine
-
Multicenter Study Clinical Trial
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. ⋯ Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.
-
Letter Case Reports
Combined aortic surgery and implantation of a left ventricular assist device.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest.
Cardiac arrest with widespread cerebral ischemia frequently leads to severe neurologic impairment. We studied whether mild systemic hypothermia increases the rate of neurologic recovery after resuscitation from cardiac arrest due to ventricular fibrillation. ⋯ In patients who have been successfully resuscitated after cardiac arrest due to ventricular fibrillation, therapeutic mild hypothermia increased the rate of a favorable neurologic outcome and reduced mortality.